Anavex Life Sciences Corp (AVXL)

[hnbadger1]

FWIW—ANVS results-

Adam Feuerstein
@adamteuerstein
Follow
$ANVS CEO Maria Maccecchini, on a call last night, admitted the failure of its buntanetap Parkinson's study:
The primary endpoint was MDS-UPDRS Part Il in the ITT population n=523
Maria: "This is the ITT population before subdividing them into the groups. And if you look at MDS-UPDRS Part II, you see that it pretty much doesn't move. The total ITT population does not change at all in MDS-UPDRS Part I!."
MDS-UPDRS Part Ill is the most important secondary endpoint. It also failed.
Maria: "Now, the MDS-UPDRS Part Ill part in the ITT population looks pretty much identical to the ITT population in our Alzheimer patients, everybody improves because that's what we see. We had high placebo, we had good response. Minus 3 is excellent response, but the placebo also has minus 3."And below is the Annovis graph showing the failure. Lowered scores in MDS-UPDRS means improvement. Placebo performed better than butanetap.
This is why Annovis is falsely touting a win on a small subgroup of study participants with a Parkinson's diagnosis of greater than 3 years. The analysis is invalid and will be laughed out of the FDA if the company tries to file on it, but that's a story for another time.